Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Randomized Controlled Semi-blinded Trial to Investigate Safety and Effectiveness in Ureter Visualization With Intravenous Nizaracianine Triflutate, in up to 3 Divided Doses, in Adults Undergoing Abdominopelvic Surgery (TRIPHASE)

NCT06101745 is registered in ClinicalTrials.gov with Curadel Surgical Innovations, Inc. as lead sponsor.

NCT NCT06101745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06101745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Randomized Controlled Semi-blinded Trial to Investigate Safety and Effectiveness in Ureter Visualization With Intravenous Nizaracianine Triflutate, in up to 3 Divided Doses, in Adults Undergoing Abdominopelvic Surgery (TRIPHASE)
Lead sponsor
Curadel Surgical Innovations, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 28, 2024
Completion date
August 31, 2026
Enrollment
336 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

injury of ureter during surgery (disorder)